reasoning
SARS-CoV-2 shares parts with two different viruses that themselves do not share those similarities with each other, indicating it is a chimera. Chimeras occur both in nature and in labs doing gain-of-function research, but this specific chimera is judged less likely to combine in nature, while the WIV is known to have had access to both parent viruses. Factors: zoonotic ÷8, zoonotic-collection ÷8, lab-escape ×2, bioweapon ×1 (neutral). Running likelihoods: Zoonotic 46%, Lab-escape 32%, Bioweapon 4.9%, Zoonotic-collection 17%. Together with the furin-cleavage factor this is Rootclaim’s strongest genetic evidence for a lab origin.
Step 6 assessment
Reconstruction. Premises: (a) SARS-CoV-2 is a chimera of two viruses that are not otherwise similar to each other; (b) this specific combination is judged less likely to arise by natural recombination than to be constructed in a GoF lab; (c) the WIV had access to both parent viruses (means/capability). Load-bearing step: rare-in-nature + a lab with the means → P(this chimera | lab GoF) > P(this chimera | natural), favoring lab.
Evaluation. Conditional on the premises this is valid likelihood reasoning: a configuration that is disfavored by the natural pathway and available to the lab pathway raises the lab-relative likelihood. The main scientific challenge — coronavirus recombination is ubiquitous, so this “chimera” is a natural-recombination signature (A-66) — attacks premise (b), not the inferential step; likewise A-60’s “backbone matches no known reverse-genetics system” bears on whether the lab pathway is actually probable and is priced as strength/premise-truth downstream. Given (b) and (c) as granted, no undercutting defeater breaks the step. Approved; step traced directly, checked.